# Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

> **NCT07554495** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Alfasigma S.p.A.** · enrollment: 65 (estimated)

## Conditions studied

- Polyarticular Course Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Filgotinib

## Key facts

- **NCT ID:** NCT07554495
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07554495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07554495, "Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07554495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*